---
title: "Descartes-08 in Generalized myasthenia gravis: Special populations"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Special populations. Topics: Age: adults in the phase 2b trial, Pediatric population: HELIOS trial including juvenile myasthenia gravis, Contraception for women of childbearing potential in AURORA, Male contraception in the phase 2b trial, and 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/special-populations"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Age: adults in the phase 2b trial

> “MG-001 part 3 was a prospective, double-blind, multicenter, randomized placebo-controlled phase 2b trial evaluating the safety and clinical activity of Descartes-08, RNA-engineered anti-BCMA CAR-T, in adults with generalized MG.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.8-2"></a>

### Pediatric population: HELIOS trial including juvenile myasthenia gravis

> “Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis”
> “At least age 12”

Source: [ClinicalTrials.gov NCT07089121](https://clinicaltrials.gov/study/NCT07089121)

> “Fully outpatient treatment with 1hr post-infusion monitoring”

Source: [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

<a id="topic-2.1.2.8-3"></a>

### Contraception for women of childbearing potential in AURORA

> “Women of childbearing potential must agree to use highly effective birth control from Screening until 14 days post last dose of Descartes-08”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-2.1.2.8-4"></a>

### Male contraception in the phase 2b trial

> “Male patients were to agree to effective contraception (for example, condoms (male or female) with or without a spermicidal agent, a diaphragm or cervical cap with spermicide, or an intrauterine device) from screening through 14 days after the last dose of Descartes-08.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.1.2.8-5"></a>

### Renal and hepatic impairment: phase 2b exclusion thresholds

> “alanine transaminase and/or aspartate transaminase levels more than three times above upper limit of normal; creatinine clearance less than 30 ml min⁻¹”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
